Profound Medicl (NYSE:PROF) – Equities research analysts at Raymond James issued their Q1 2021 earnings per share (EPS) estimates for shares of Profound Medicl in a research note issued on Monday, January 27th. Raymond James analyst R. Sarugaser anticipates that the company will post earnings per share of ($0.36) for the quarter. Raymond James currently has a “Strong-Buy” rating on the stock. Raymond James also issued estimates for Profound Medicl’s Q2 2021 earnings at ($0.32) EPS, Q3 2021 earnings at ($0.28) EPS, Q4 2021 earnings at ($0.23) EPS and FY2024 earnings at $3.82 EPS.
Profound Medicl (NYSE:PROF) last posted its quarterly earnings data on Thursday, November 7th. The company reported ($0.43) earnings per share (EPS) for the quarter. The company had revenue of $0.52 million for the quarter.
Separately, Echelon Wealth Partners reissued a “buy” rating on shares of Profound Medicl in a report on Friday, November 8th.
PROF opened at $14.20 on Wednesday. The business has a 50 day simple moving average of $11.16. Profound Medicl has a 12-month low of $5.00 and a 12-month high of $14.40.
Profound Medicl Company Profile
Profound Medical Corp. operates as a medical technology company focuses on magnetic resonance guided ablation procedures in Canada, Germany, and Finland. It is developing a treatment to ablate the prostate gland in prostate cancer patients, treatment of uterine fibroids and nerves, and palliative pain treatment for patients with metastatic bone disease.
Further Reading: Cash Flow
Receive News & Ratings for Profound Medicl Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Profound Medicl and related companies with MarketBeat.com's FREE daily email newsletter.
